Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 13/20 | 0.77 |
| ▸ | IDH1 | O75874 | 13/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18774522 | 0.97 | IDH2 (0.75) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774517 | 0.94 | IDH2 (0.85) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774526 | 0.92 | IDH1 (0.67) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774535 | 0.92 | IDH2 (0.67) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774533 | 0.91 | IDH2 (0.66) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL17891027 | 0.90 | IDH2 (0.87) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774538 | 0.89 | IDH2 (0.68) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774516 | 0.89 | IDH2 (0.70) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774525 | 0.89 | IDH1 (0.70) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774515 | 0.88 | IDH2 (0.72) | IDH2IDH1ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688659-B2 | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof | NeuForm Pharmaceuticals, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170114041-A1 | DEUTERATED COMPOUNDS FOR TREATING HEMATOLOGIC MALIGNANCIES, AND COMPOSITIONS AND METHODS THEREOF | NEUFORM PHARMACEUTICALS INC (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114041-A1 | DEUTERATED COMPOUNDS FOR TREATING HEMATOLOGIC MALIGNANCIES, AND COMPOSITIONS AND METHODS THEREOF | MCL1, HCLS1, BCL9 | IDH2 180/4885IDH1 307/4885ABCB11 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.